Vixarelimab

Names

[ Name ]:
Vixarelimab

Biological Activity

[Description]:

Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash[1].

[Related Catalog]:

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

Research Areas >> Inflammation/Immunology

[In Vitro]

Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) 在浓度为 0.0001 μg/mL 时，导致人表皮角质形成细胞 (HEK) 和人真皮成纤维细胞 (HDF) 的 MCP-1/CCL2 水平升高，当浓度为 0.001 μg/mL 或更高时，两种细胞的 MCP-1/CCL2 水平显著降低[1]。 Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) 预处理使得在 Oncostatin M（OSM）诱导的以及 OSM + IL-4 诱导的 HEK 和 HDF 细胞中，都降低了 MCP-1/CCL2 的水平，并且在浓度为 0.01 μg/mL 和 0.1 μg/mL 时观察到最大的效果[1]。

[References]

[1]. Carl D Richards, et al. Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716. Acta Derm Venereol. 2020 Jul 2;100(14):adv00197.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.